간질 시장에 대해 조사했으며, 간질 치료의 동향에 관한 키 업계 리더의 최신 인사이트를 파악할 수 있습니다. 현재 치료법의 유효성, 신약의 가능성, 진화하는 관리 전략에 대해 심층 분석하고 있습니다. 미충족 요구 및 신규 치료의 벤치마크에도 언급하며, 간질 치료의 미래에 대해 종합적으로 정리하여 전해드립니다.
본 리포트의 주요 브랜드
- Belviq(lorcaserin)
- Briviact(brivaracetam)
- Comfyde(carisbamate)
- Diacomit(stiripentol)
- Epidiolex/Epidyolex(cannabidiol)
- EPX-100(clemizole)
- EQU-001(ivermectin capsule formulation)
|
- Fintepla(fenfluramine)
- Fycompa(perampanel)
- STK-001(zorevunersen)
- TAK935(soticlestat)；Xcopri/Ontozry(cenobamate)
- XEN1101(azetukalner)
- Ztalmy(ganaxolone)
|
기업 리스트
- UCB
- Jazz Pharmaceuticals
- SK Life Science
- Takeda
- Marinus Pharmaceuticals
- Xenon Pharmaceuticals
|
- Eisai
- Stoke Therapeutics
- Epygenix Therapeutics
- Biocodex
- Equilibre Biopharmaceuticals
|
KSA
Discover the latest insights from key opinion leaders on epilepsy treatment trends. This report delves into the efficacy of current therapies, the potential of emerging drugs, and evolving management strategies. It addresses unmet needs and benchmarks for new treatments, offering a comprehensive view of the future landscape in epilepsy care.
Key questions answered:
- How do current epilepsy treatments compare in terms of efficacy, side effects, and ease of use?
- Which upcoming epilepsy therapies show the most potential for improving patient outcomes?
- What benchmarks must new epilepsy drugs meet to remain competitive in the market?
- How will new treatments impact the current landscape of epilepsy medications?
- How is epilepsy management expected to evolve for different patient populations?
- What are the key unmet needs in existing epilepsy treatments that still need to be addressed?
Key brands covered in this report:
- Belviq (lorcaserin)
- Briviact (brivaracetam)
- Comfyde (carisbamate)
- Diacomit (stiripentol)
- Epidiolex/Epidyolex (cannabidiol)
- EPX-100 (clemizole)
- EQU-001 (ivermectin capsule formulation)
|
- Fintepla (fenfluramine)
- Fycompa (perampanel)
- STK-001 (zorevunersen)
- TAK 935 (soticlestat); Xcopri/Ontozry (cenobamate)
- XEN1101 (azetukalner)
- Ztalmy (ganaxolone)
|
List of Companies:
- UCB
- Jazz Pharmaceuticals
- SK Life Science
- Takeda
- Marinus Pharmaceuticals
- Xenon Pharmaceuticals
|
- Eisai
- Stoke Therapeutics
- Epygenix Therapeutics
- Biocodex
- Equilibre Biopharmaceuticals
|
Table of Tables
Executive summary
Treatment algorithm
Research objectives
Marketed therapies
- Sodium channel blockers
- Carbamazepine-related antiseizure medications
- Xcopri/Ontozry (cenobamate; SK Life Science)
Neuromodulators
- Briviact (brivaracetam; UCB)
GABAergic mechanisms
- Benzodiapines (rescue medications)
- Key insights summary
- Ztalmy (ganaxolone; Marinus Pharmaceuticals)
- Diacomit (stiripentol; Biocodex)
Other modes of action
- Epidiolex/Epidyolex (cannabidiol; Jazz Pharmaceuticals)
- Key insights summary
- Fintepla (fenfluramine; UCB)
- Fycompa (perampanel; Eisai)
Pipeline therapies
- Late-stage drugs
- Belviq (lorcaserin; Eisai)
- TAK 935 (soticlestat; Takeda)
- Comfyde (carisbamate; SK Life Science)
- Early-stage drugs
- XEN1101 (azetukalner; Xenon Pharmaceuticals)
- EPX-100 (clemizole; Epygenix Therapeutics)
- EQU-001 (ivermectin capsule formulation; Equilibre Biopharmaceuticals)
- STK-001 (zorevunersen; Stoke Therapeutics)
Future treatment paradigm
- Key insights summary
- Anti-epileptogenesis and disease-modifying treatments emerge as key unmet needs in epilepsy, alongside improved diagnostics and targeted therapies
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
KOL Bulletins
